Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities researchers at Truist Securiti issued their Q1 2022 earnings per share (EPS) estimates for shares of Marinus Pharmaceuticals in a report released on Monday, September 20th. Truist Securiti analyst J. Lee anticipates that the biopharmaceutical company will post earnings of ($0.70) per share for the quarter. Truist Securiti also issued estimates for Marinus Pharmaceuticals’ Q3 2022 earnings at ($0.73) EPS.
A number of other equities research analysts have also issued reports on MRNS. SVB Leerink reiterated a “buy” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, August 19th. JMP Securities reissued a “buy” rating and issued a $23.00 price target on shares of Marinus Pharmaceuticals in a report on Monday. Truist Securities increased their price objective on shares of Marinus Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 18th. Zacks Investment Research lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 14th. Finally, Truist boosted their price target on shares of Marinus Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, August 18th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $29.11.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 10th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.03.
Several institutional investors have recently bought and sold shares of MRNS. Citigroup Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 32.8% in the 2nd quarter. Citigroup Inc. now owns 5,629 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 1,390 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Marinus Pharmaceuticals by 9.0% during the first quarter. The Manufacturers Life Insurance Company now owns 17,256 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 1,430 shares during the period. Vectors Research Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $36,000. Alliancebernstein L.P. boosted its holdings in shares of Marinus Pharmaceuticals by 11.1% in the 2nd quarter. Alliancebernstein L.P. now owns 20,024 shares of the biopharmaceutical company’s stock worth $359,000 after purchasing an additional 2,000 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 2.5% in the 1st quarter. Nuveen Asset Management LLC now owns 85,974 shares of the biopharmaceutical company’s stock worth $1,331,000 after purchasing an additional 2,073 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
Read More: How dollar cost averaging works
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.